Ex­elix­is, Te­va reach set­tle­ment on Cabome­tyx patent dis­pute

Ex­elix­is has set­tled a patent dis­pute over Te­va’s at­tempt to mar­ket a gener­ic ver­sion of its block­buster can­cer drug Cabome­tyx, push­ing gener­ic com­pe­ti­tion in­to the next decade.

The set­tle­ment re­solves a case brought by Ex­elix­is in Delaware fed­er­al court over a patent that ex­pires in 2032 and cov­ers process­es to make com­pounds con­tain­ing quino­lines, a type of or­gan­ic com­pound. As part of the deal, Ex­elix­is has agreed to give Te­va a li­cense to mar­ket its gener­ic ver­sion on Jan. 1, 2031, pend­ing FDA ap­proval, Ex­elix­is an­nounced Sun­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER